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An Electronic Vapour Product (EVP) has been evaluated for short-term safety parameters and subjective
effects in a 2-part study, in smokers. Part 1 compared the EVP with unﬂavoured (UF) and ﬂavoured (FL) e-
liquid at 2.0% nicotine to a conventional cigarette (CC; JPS Silver King Size, 0.6 mg) and a licensed nicotine
inhalator (Nicorette®, 15 mg). Part 2 assessed the effect of increasing concentrations of nicotine in the e-
liquid used with the EVP (0%, 0.4%, 0.9%, 2.0%). The study was designed as a randomised, controlled,
crossover trial. Outcomes included adverse events (AEs), vital signs, exhaled carbon monoxide (CO),
clinical laboratory parameters, smoking urges and withdrawal symptoms. In both study parts, only mild
non-serious AEs were reported. No major differences were observed in AEs between the EVPs and
Nicorette®. Exhaled CO levels only increased for CC. All products appeared to decrease smoking urges and
nicotine withdrawal symptom scores to a similar extent. The EVP had a similar short-term safety proﬁle
to Nicorette® and relieved smoking urges and nicotine withdrawal symptoms to a similar extent as
Nicorette® and CC. Unlike nicotine replacement therapies, the EVP may offer an alternative for those
ﬁnding it difﬁcult to quit the behavioural and sensorial aspects of smoking.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Electronic vapour products (EVPs), also known as “electronic
cigarettes” are a relatively new class of products. Even though the
majority of EVPs are marketed as consumer products, they are often
reported to be used as a means to stop smoking conventional cig-
arettes (Berg et al., 2015; Dockrell et al., 2013; Etter and Bullen,
2011). Any claims to cessation or harm reduction must require a
medicinal license (MHRA, 2015). The few short-term studies per-
formed to date suggest that EVPs have the potential for being safer
alternatives to conventional cigarettes (CC) and at the same time
satisfy the ritualistic elements of smoking. For example, EVPs do
not increase exhaled carbon monoxide (CO) levels or white blood
cell count, and do not have immediate effects on myocardial andonal cigarettes; CO, Carbon
tine replacement therapy.
(T. Walele).
r Inc. This is an open access articlelung functions (Farsalinos, 2012; Flouris et al., 2013, 2012; Vansickel
et al., 2010; Vardavas et al., 2012). When smokers switch to use
EVPs and are followed-up for prolonged periods, observations have
included a progressive decrease in occurrences of adverse events
(AEs) commonly reported by CC smokers, e.g. cough, dry mouth,
shortness of breath, throat irritation and headache (Caponnetto
et al., 2013; Farsalinos et al., 2014a; Polosa et al., 2014; van
Staden et al., 2013). A higher frequency of mouth and throat irri-
tation was observed in smokers switching to using a Nicorette®
inhalator, compared to those using EVPs (Bullen et al., 2010). Few
commercially available EVPs have been studied for their subjective
effects such as the suppression of desire to smoke and tobacco or
nicotine abstinence symptoms. Some studies have demonstrated
that evenwith no nicotine present in EVP e-liquid, nicotine craving
and withdrawal symptoms were alleviated albeit less compared to
CCs (Bullen et al., 2010; Vansickel et al., 2010).
This study was conducted as part of a product stewardship
evaluation of an EVP prototype. The evaluation of the product's
plasma nicotine pharmacokinetic (PK) proﬁle is reported elsewhereunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the potential of the EVP for reducing smoking urges and with-
drawal symptoms are described. The study consisted of two parts.
Part 1 compared the EVP with an unﬂavoured (UF) and a ﬂavoured
(FL) e-liquid containing 2.0% nicotine to a nicotine replacement
therapy (NRT) product and a commercially available CC. Part 2
investigated the effects of the EVP with unﬂavoured e-liquids
containing increasing levels of nicotine (0%, 0.4%, 0.9% and 2.0%).
2. Materials and methods
2.1. Study design
This study was performed at a single clinical site (Simbec
Research Ltd, Wales) in a conﬁnement setting. A total of 24 healthy
male subjects, recruited in the UK, participated in the study: 12
assigned to Part 1 and 12 to Part 2. Both study parts were designed
as a randomised, controlled, four-way crossover trial. Part 1 was
performed open-label and Part 2 was blinded. Following overnight
abstinence from smoking or using EVPs, subjects used each
different product for one daily use session.
The study was approved by the South East Wales Research
Ethics Committees on 31 October 2013, and is registered at the US
National Institutes of Health (ClinicalTrials.gov) #NCT02032212. All
procedures were performed in accordance with the International
Conference on Harmonisation (ICH) Harmonised Tripartite Guide-
line for Good Clinical Practice (GCP). The Medicines and Healthcare
Products Regulatory Agency (MHRA)-UK granted Clinical Trials
Authorisation (CTA) for the use of the NRT product in this study. All
subjects signed an informed consent form prior to any study pro-
cedures being performed.
2.2. Study population
Detailed inclusion and exclusion criteria are presented in our
paper reporting the plasma PK results (Walele et al., 2015). Subjects
were 21e65 year old males and were conﬁrmed smokers (5e30
cigarettes per day for at least one year). The subjects’ smoking
history was recorded using internal questionnaires and with the
Fagerstr€om Test for Nicotine Dependence (FTND) (Heatherton et al.,
1991). Subjects were excluded if they were taking or receiving any
form of NRT, snuff or chewing tobacco or if they intended to stop
smoking.
2.3. Products used in this study
The EVP prototype used in this study was developed by Fontem
Ventures B.V. It consisted of a rechargeable battery, an atomiser and
a capsule containing e-liquid (Fig. 1). The capsules were replaceable
and the battery and atomiser were reusable. The base components
of the e-liquids used are propylene glycol (70e75% w/w), glycerol
(18e20%w/w) andwater (5%w/w). Two e-liquids were used in PartFig. 1. Schematic of the external appearance and parts of the tested EVP. From left to
right, pieces are: the housing, which contains the battery and has a LED indicator on
the side, the atomiser, the capsule containing the e-liquid and the mouthpiece.1 of the study, which differed solely in their ﬂavour content: an
unﬂavoured base e-liquid with 2.0% nicotine (UF2.0%; 2.7 mg/
capsule) and a ﬂavoured (menthol) e-liquid with 2.0% nicotine
(FL2.0%; 2.7 mg/capsule). In Part 2, four unﬂavoured e-liquids were
used, which differed in their nicotine content: 0% nicotine (UF0%),
0.4% nicotine (UF0.4%; 0.4%; 0.54 mg/capsule), 0.9% nicotine
(UF0.9%; 1.22mg/capsule) and UF2.0%. The EVPwith UF2.0%, FL2.0%
and UF0.4% delivers mean amounts of 0.013, 0.007 and 0.002 mg
nicotine per puff, respectively (internal data, generated under
Health Canada Intense smoking regime). Nicotine delivery with
UF0.9% was not measured.
In Part 1 of the study, the NRT Nicorette® Inhalator (15 mg
nicotine, manufacturer Johnson & Johnson; coded NIC15) was used
as a comparator product and a JPS Silver King Size CC (0.6 mg
nicotine; manufacturer Imperial Tobacco Group) was used as a
control.2.4. Study interventions and schedule
Subjects were admitted to the study site on the morning of
Day 2 (baseline) for conﬁrmation of eligibility and training on
using the EVP or NIC15. Smoking status was veriﬁed by measuring
the urinary cotinine levels in a spot urine sample (NicAlert strip),
the exhaled CO levels (measured with a portable Bedfont
Micro þ Smokerlyser device) and blood carboxyhemoglobin
(COHb) levels (2 mL sample, from a forearm vein, in lithium hep-
arin, measured with a blood gas analyser system). A safety
assessment was performed on Day 2, which included vital signs
(blood pressure, heart rate and oral body temperature in supine
position), AEs, a physical exam, a lung function test (spirometry)
and a 12-lead electrocardiogram (ECG). Blood (7.6mL, from forearm
vein) and urine samples were taken to measure haematology,
clinical chemistry and urinalysis parameters, for standard clinical
laboratory evaluations. From the time of admission, subjects were
not permitted to use any EVP, NRTor CC other than that assigned by
the study design and were not allowed to consume alcohol. Sub-
jects remained in conﬁnement until the end of the study period, on
the morning of Day 5. On Day 1, the revised Minnesota Nicotine
Withdrawal Scale questionnaire (MWS-R) was administered to
document nicotine withdrawal symptoms (Hughes, 2007) and the
Brief Questionnaire of Smoking Urges (QSU-Brief), to measure
craving (Cox et al., 2001). On Day 1, subjects were randomly
assigned to one of four pre-deﬁned sequences of product use
within their allocated study Part, in a 3:3:3:3 ratio.
On study Days 1, 2, 3, and 4, after overnight smoking abstinence,
subjects used the allocated product for four product administra-
tions at 1-h intervals (0hr, 1hr, 2hr and 3hr). Each administration
consisted of 10 inhalations at 30 s intervals. Each inhalation was
monitored, and subjects were instructed to take 4-s puffs for the
EVP and NIC15, and 2-s puffs for the CC (an electronic tablet was
used instructing subjects when to inhale and exhale). Vital signs
were recorded approximately 30 min before the ﬁrst product
administration, and 30 min after the fourth one. Exhaled CO was
measured 5 min before and 25 min after each product adminis-
tration. Subjects ﬁlled the MWS-R and QSU-Brief questionnaires
approximately 30 min after the third administration, at a similar
timing as on Day1. These assessments were done 30min after the
fourth administration because priority was given to PK sampling
(Walele et al., 2015). AEs were monitored on each study day.
On Day 5, safety assessment parameters were checked, and
subjects answered both the MWS-R and QSU-Brief questionnaires
for the last time. Subjects were also provided full verbal smoking
cessation advice by the investigator and were discharged from the
clinic after all study assessments were performed.
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Randomisation of subjects to one of the four product use se-
quences was performed according to randomisation codes pro-
duced using the PROC PLAN procedure of SAS® version 9.4.
2.6. Study outcome measures
Safety assessment measures included vital signs, 12-lead ECG,
lung function tests, exhaled CO, monitoring of AEs and standard
haematology, clinical biochemistry and urinalysis parameters
(Table 1).
Withdrawal symptoms were evaluated with a modiﬁed MWS-R
questionnaire (Hughes, 2007), towhich only the 15 questions of the
subject's part were completed. Subjects had to rate behaviours (e.g.
angry, irritable, frustrated, depressed, restless, insomnia) from
0 (none) to 4 (severe). Craving was assessed with the QSU-Brief
questionnaire. Subject had to rate 10 statements, such as “I have a
desire for a cigarette right now”, by a number ranging from 1
(strongly disagree) to 7 (strongly agree) (Cox et al., 2001).
2.7. Bioanalytical methods
COHb in whole blood samples was assessed with the Roche
Cobas B221 Blood Gas Analyser System using a spectrophotometric
method (Roche, 2009). Haematology samples were analysed using
the Siemens Advia 2120® or Siemens Advia 120® using commer-
cially available kits. Clinical biochemistry samples were analysed
using the Roche Modular Analytics System® using commercially
available kits. Urinalysis parameters were measured using the
Siemens Clinitek 500 analyser.
2.8. Statistical methods
2.8.1. Sample size
The sample size was mainly determined for nicotine bioavail-
ability comparisons (Walele et al., 2015) and was selected based on
similar PK studies on similar products (Bullen et al., 2010; Dawkins
and Corcoran, 2014; Farsalinos et al., 2014b) and guidance from
competent authorities (EMA, 2010; HC, 2012). Twelve subjects per
study part were considered sufﬁcient in the crossover design, as all
subjects used each of the four different products.
2.8.2. Safety parameters
In order to avoid an effect of multiple comparisons, no speciﬁc
statistical analyses have been performed on the safety parameters.
Descriptive statistics were calculated for continuous values and
frequencies for categorical variables.Table 1
Study outcome measures.
Outcome measure Detail of measured parameters
Vital signs Supine systolic and diastolic blood pressure, pulse rate and oral tem
12-lead ECG Heart rate, PR interval, QSR width, QT interval and QTcB interval
Lung function
tests
lung function tests: FVC and % predicted FVC (FVC%pred.), FEV1 and
predicted FEF25-75 (FEF25-75%pred.), peak expiratory ﬂow (PEF) and % p
pred.)
Exhaled CO Exhaled CO
AEs Monitoring of AEs along with severity grades and relationship to p
(MedDRA), version 16.1, 2013.
Haematology Haemoglobin, haematocrit, mean cell volume, mean cell haemoglo
neutrophils, lymphocytes, monocytes, eosinophils, basophils and p
Clinical
biochemistry
Total protein, albumin, total bilirubin, inorganic phosphorus, alkali
transferase, glucose, sodium, potassium, chloride, blood urea nitrog
Urinalysis pH, protein, glucose, ketones, urobilinogen, blood and speciﬁc grav2.8.3. Withdrawal and craving parameters
For the MWS-R questionnaire, the sum of the scores of the ﬁrst
nine questions was calculated (core score), as well as the sum of all
15 questions (total score). For the QSU-Brief questionnaire, the sum
of the scores of all 10 questions was calculated, as well as the sum of
the scores for questions 1, 3, 6, 7 and 10 (Factor 1; desire and
intention to smoke with smoking anticipated as pleasurable) and
the sum of the scores for questions 2, 4, 5, 8 and 9 (Factor 2;
anticipation of relief from negative effect and nicotine withdrawal).
For both questionnaires, descriptive statistics (mean scores and
standard deviations) were calculated.
3. Results
3.1. Subjects’ characteristics
Subjects were screened from January 2014 to March 2014. All 24
enrolled subjects completed the study according to the protocol
(see methods). There were no withdrawals. Detailed subjects’
characteristics are provided elsewhere (Walele et al., 2015).
3.2. Safety
3.2.1. Adverse events
Table 2 summarises the AEs reported during both study parts.
None of the subjects reported anymoderate or serious AE and there
were no AEs leading to study withdrawal. In Part 1, 5/12 subjects
(41.7%) reported a total of 12 AEs, which were evaluated as mild.
Given the overall low number of AEs, no clear product-trends were
observed. In Part 2, 7/12 subjects (58.3%) reported a total of 13 AEs,
all of which were evaluated as mild. As in Part 1, no clear product-
related trend was observed, even though most AEs occurred with
the products containing the highest nicotine concentrations.
Cough, reported by two subjects using UF2.0% and one subject
using UF0.9%, was the most common AE.
3.2.2. Exhaled CO
In Part 1, exhaled CO levels increased with each CC adminis-
tration, reaching amaximumvalue of 14.8 ppm 25min after the 4th
administration, compared tomaximumvalues of 2.5 ppm following
UF2.0%, 2.2 ppm after FL2.0% and 2.3 ppm after NIC15 (Fig. 2).
In Part 2, there were no dose-related effects on CO levels, as
reﬂected by similar mean values of approximately 2e3 ppm
observed following each administration of UF0%, UF0.4%, UF0.9%
and UF2.0% (Fig. 3).
3.2.3. Other safety parameters
For both Part 1 and Part 2 of the study, there were no clinicallyperature
% predicted FEV1 (FEV1%pred.), forced expiratory ﬂow 25%e75% (FEF25-75) and %
redicted PEF (PEF%pred.), FEV1/FVC ratio and % predicted FEV1/FVC ratio (FEV1/FVC%
roduct. All AEs were coded using the Medical Dictionary for Regulatory Activities
bin, mean cell haemoglobin concentration, red blood cells, white blood cells,
latelets
ne phosphatase, alanine transaminase, aspartate transaminase, gamma glutamyl
en, creatinine and calcium
ity
Table 2
Number of subjects (%) reporting AEs and number of AEs by relationship and by SOC for each product in Part 1 and Part 2.
Part 1
UF2.0% FL2.0% NIC15 CC Overall
(N ¼ 12) (N ¼ 12) (N ¼ 12) (N ¼ 12) (N ¼ 12)
Number of AEs 2 3 7 0 12
Number (%) subjects with 1 AE: 1 (8.3%) 3 (25.0%) 3 (25.0%) 0 5 (41.7%)
Number (%) of subjects with AE/number of AEs by relationship
Related 1 (8.3%)/2 2 (16.7%)/2 3 (25.0%)/7 0 4 (33.3%)/11
Unrelated 0 1 (8.3%)/1 0 0 1 (8.3%)/1
Number (%) of subjects with AE/number of AEs by SOC
Gastrointestinal disorders
Glossodynia (related) 0 0 1 (8.3%)/1 0 1 (8.3%)/1
Infection and infestation
Nasopharyngitis (unrelated) 0 1 (8.3%)/1 0 0 1 (8.3%)/1
Respiratory, thoracic and mediastinal disorders:
Cough (related) 1 (8.3%)/2 1 (8.3%)/1 2 (16.7%)/5 0 2 (16.7%)/8
Throat irritation (related) 0 1 (8.3%)/1 1 (8.3%)/1 0 2 (16.7%)/2
Part 2
UF2.0% UF0.9% UF0.4% UF0% Overall
(N ¼ 12) (N ¼ 12) (N ¼ 12) (N ¼ 12) (N ¼ 12)
Number of AEs 6 3 3 1 13
Number (%) subjects with 1 AE: 3 (25.0%) 3 (25.0%) 3 (25.0%) 1 (8.3%) 7 (58.3%)
Number (%) of subjects with AE/number of AEs by relationship:
Related 2 (16.7%)/3 1 (8.3%)/1 0 0 3 (25.0%)/4
Unrelated 1 (8.3%)/3 2 (16.7%)/2 3 (25.0%)/3 1 (8.3%)/1 4 (33.3%)/9
Number (%) of subjects with AE/number of AEs by SOC
Gastrointestinal disorders:
Toothache (unrelated) 0 1 (8.3%)/1 0 0 1 (8.3%)/1
General disorders and administration site conditions:
Fatigue (unrelated) 1 (8.3%)/1 0 1 (8.3%)/1 0 2 (16.7%)/2
Musculoskeletal and connective tissue disorders:
Myalgia (unrelated) 0 1 (8.3%)/1 0 0 1 (8.3%)/1
Musculoskeletal and connective tissue disorders:
Dizziness (unrelated) 1 (8.3%)/1 0 0 1 (8.3%)/1 2 (16.7%)/2
Headache (unrelated) 0 0 2 (16.7%)/2 0 2 (16.7%)/2
Paraesthesia (unrelated) 1 (8.3%)/1 0 0 0 1 (8.3%)/1
Respiratory, thoracic and mediastinal disorders:
Cough (related) 2 (16.7%)/3 1 (8.3%)/1 0 0 3 (25.0%)/4
Note. SOC, system organ class.
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amination ﬁndings. At baseline and at Day 5 therewere no clinically
signiﬁcant 12-lead ECG or lung function test ﬁndings, for any
product in either study part. There were no product-related effects
on vital signs during Part 1 of the study, as reﬂected by similar
mean values for each parameter pre-administration (30 min before
the ﬁrst administration) and post-administration (30 min after theFig. 2. Mean (±SEM) exhaled CO levels 5 min before and 25 min after each product
administration. Twelve subjects received each product in a crossover design. CO, car-
bon monoxide; UF2.0%, unﬂavoured base e-liquid at 2.0% nicotine; FL2.0%, ﬂavoured
base e-liquid at 2.0% nicotine; NIC15, Nicorette® Inhalator 15 mg nicotine; SEM,
standard error of the mean.4th administration) of UF2.0%, FL2.0%, NIC15 and CC (data not
shown). There were no dose-related effects on vital signs during
Part 2 of the study, as reﬂected by similar mean values for each
parameter pre-administration and following administration of
UF0%, UF0.4%, UF0.9% and UF2.0% (data not shown).Fig. 3. Mean (±SEM) exhaled CO levels 5 min before and 25 min after each product
administration. Twelve subjects received each product in a crossover design. CO, car-
bon monoxide; UF2.0%, unﬂavoured base e-liquid at 2.0% nicotine; UF0.9%, unﬂavoured
base liquid at 0.9% nicotine; UF0.4%, unﬂavoured base liquid at 0.4% nicotine and UF0%,
unﬂavoured base liquid at 0% nicotine; SEM, standard error of the mean.
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3.3.1. MWS-R questionnaire
Mean total scores of the MWS-R questionnaire by product, for
Part 1 and Part 2 of the study, are shown in Table 3.
In Part 1, the mean total score was 9.80 on Day 1 and slightly
decreased to a range of 6.40e8.10 on Days 1e4, regardless of the
administered product. The scores were similar for UF2.0%, FL2.0%,
NIC15 and the CC. On Day 5, the total score increased slightly to
reach 9.50. These results indicate that UF2.0%, FL2.0%, NIC15 and
the CC induced a small reduction of nicotinewithdrawal symptoms,
and did so to a similar extent. Results from the core scores showed a
similar trend (not shown). In Part 2, all four products decreased the
mean total score from a level of 13.20 on Day 1 to a range of
7.30e9.00 on Days 1e4. UF0%, UF0.4%, UF0.9% and UF2.0% had
similar mean total scores, indicating that the level of nicotine had
no inﬂuence on withdrawal symptoms. On Day 5, the total score
decreased slightly further to a mean level of 5.30. Core scores
indicated similar trends (data not shown).
3.3.2. QSU-Brief questionnaire
Mean total scores of the QSU-Brief questionnaire are summar-
ised in Table 3. During Days 1e4 of Part 1, total scores were similar
for UF2.0%, FL2.0%, NIC15 and the CC, and ranged from 22.80 to
25.60. They were lower than the total score of 38.00 on Day 1 and
that of 31.40 on Day 5, which indicates that all four products
reduced urge to smoke to a similar extent. The pattern was similar
for Factor 1 and Factor 2 scores (data not shown). In Part 2, the total
mean score reached 41.90 on Day1, and on Days 1e4 was reduced
to mean scores ranging from 31.50 to 34.90, regardless of the
administered product. The total score increased to a mean of 33.00
on Day 5. These results indicate that all four products could slightly
reduce craving. Since the study was not powered to perform sta-
tistical analyses on the secondary outcomes, no ﬁrm conclusions
can be drawn on the inﬂuence of nicotine level on the question-
naire scores and that there was no inﬂuence of the nicotine level.
Factor 1 and Factor 2 scores followed a similar trend (data not
shown).
As the Day 5 questionnaires were performed at an earlier time of
the day than those of Days1 to 4, the results fromDay 5, although
presented here, have not been taken into account for the
interpretation.
4. Discussion
Here we present the safety data of a clinical study performed onTable 3














End of study (Day 5)
All values are mean (standard deviation). For Study Days 1e4, mean scores were calcula
before answering the questionnaires.an EVP prototype, along with data on smoking urges and nicotine
withdrawal symptoms. We have previously shown that the plasma
nicotine pharmacokinetics of the EVP with 2% nicotine e-liquids is
similar to the Nicorette® inhalator (Walele et al., 2015). Overall, the
EVP containing doses of nicotine ranging from 0 to 2% with and
without ﬂavourings was well tolerated and was observed to
decrease smoking urges and tobacco withdrawal symptoms in
smokers during a short-term use. At study completion, there were
no clinically signiﬁcant ﬁndings in 12-lead ECG and in lung function
test results for all subjects. Regarding exhaled CO, increases were
only observed in subjects using the CC. Exhaled CO levels did not
change from baseline levels following four administrations of EVPs
and NIC15. This ﬁnding is in agreement with other published
studies where smokers used an EVP in short, controlled sessions
(Flouris et al., 2013; Vansickel et al., 2010).
In both study parts, the use of the EVP was associated with very
few AEs, all of which were mild. The two most common AEs, cough
and throat irritation, have also been reported elsewhere as side
effects of EVPs, both following acute exposure and with regular use
in real-life settings (Bullen et al., 2010; Caponnetto et al., 2013;
Dawkins and Corcoran, 2014; Farsalinos et al., 2014a; Polosa et al.,
2014). Throat irritation was also reported as one of the most
common AEs when using a new nicotine inhaler (Moyses et al.,
2015). In the ﬁrst part of our study, both the ﬂavoured and the
unﬂavoured EVPs had an AE proﬁle similar to NIC15. Bullen et al.,
however, found a signiﬁcantly higher incidence of mouth and
throat irritation in subjects using a 10 mg Nicorette® inhalator,
compared to a 0mg and a 16mg EVP (approx.1.6% nicotine) (Bullen
et al., 2010). In that study, subjects used the products for a whole
day, whereas in our study, the product was used for four admin-
istrations, 1 h apart. None of the subjects in our study reported AEs
when using the CC. As subjects were regular, conﬁrmed smokers of
CC it is anticipated that they were used to the effects of smoking a
CC.
The different nicotine levels used had no impact on the inci-
dence and nature of AEs, except for mild cough, observed to occur
only following the use of the two highest nicotine strengths. As the
incidences were low and no statistical analysis was performed, a
clear effect of nicotine concentration on cough cannot be
concluded. Bullen et al. did not ﬁnd any difference in reported AEs
between a 0 mg and a 16 mg electronic cigarette, except for mouth
and throat irritation, which was more common with the 16 mg
nicotine EVP (Bullen et al., 2010).
None of the EVPs used in this study had any measureable effect
on blood pressure or pulse rate. In Part 1 of our study, CC smoking
did not impact pulse rate or blood pressure. As these parametersMWS-R total QSU-Brief total
9.80 (7.03) 38.00 (9.77)
6.40 (6.52) 24.80 (11.50)
6.80 (7.32) 25.00 (12.93)
7.50 (7.08) 25.60 (12.03)
8.10 (8.93) 22.80 (14.19)
9.50 (8.47) 31.40 (12.22)
13.20 (11.54) 41.90 (12.92)
7.30 (6.48) 34.90 (19.67)
8.50 (6.53) 34.80 (15.05)
9.00 (9.77) 31.90 (19.60)
7.80 (5.89) 31.50 (18.06)
5.30 (4.86) 33.00 (19.48)
ted over the four days, for each product. Subjects did not use any product on Day 5,
T. Walele et al. / Regulatory Toxicology and Pharmacology 74 (2016) 193e199198were measured 30 min after the last administration, transient ef-
fects may have been missed. Indeed, in the study performed by
Vansickel et al., (Vansickel et al., 2010) heart rate was monitored as
from 5 min after the onset of product use, and subjects smoking a
CC had a sharp increase in heart rate at 5 min, followed by a
decrease to reach rates close to baseline at 30 min. Farsalinos et al.
also observed a signiﬁcant increase in diastolic blood pressure in
EVP users, 5 min after the use session. Increased heart rate and
blood pressure are known physiological effects of nicotine
(Benowitz, 1997). In our study, the use of UF2.0% produced a
maximum mean plasma nicotine level (Cmax) of 3.6 ng/mL, 9 min
after the fourth product administration. FL2.0% produced a Cmax of
2.5 ng/mL, reached after 10min (Walele et al., 2015). In comparison,
the CC produced a Cmax of 21.2 ng/ml reached in 3 min and NIC15 a
Cmax of 2.5 ng/ml, in 13 min. Consequently, in our study, the plasma
nicotine levels may have been too low to trigger heart rate and
blood pressure increases. According to recent studies, heart rate
increases were observed in experienced EVP users who also dis-
played signiﬁcant increases in plasma nicotine levels (Spindle et al.,
2015; Vansickel and Eissenberg, 2013).
Despite not reaching high nicotine levels in blood (the EVP with
0%, 0.4%, 0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9
and 3.6 ng/mL, respectively), nicotine craving and withdrawal
symptoms slightly decreased during the EVP use sessions
compared to baseline. All EVPs, including UF0%, decreased both
MWS-R and QSU-Brief scores to a similar extent when compared to
the CC and NIC15. This is in agreement with ﬁndings from others
(Bullen et al., 2010; Vansickel et al., 2010). A recent study using a
novel nicotine inhaler showed a slight but signiﬁcant reduction in
craving and smoking urges when compared to a 10 mg Nicorette
inhalator (Moyses et al., 2015). The inhaler was shown to result in
lower venous plasma Cmax (<4 ng/mL) than use of a Nicorette
product (6e8 ng/mL). The time to Cmax however was shorter, sug-
gestive of pulmonary rather than oral absorption of nicotine, as is
the case for Nicorette. Corresponding data following use of a CCwas
not reported in that study so no further conclusions can be drawn.
The results in this study suggest that the behavioural aspects of
EVP use may contribute to the reduction of both smoking urges and
withdrawal symptoms as supported by the observation that the use
of UF0% also produced small reductions in these scores. This
observation may also partly be due to a psychological relief to use
any inhalable product, as subjects, who were conﬁrmed smokers of
CC, were not allowed to use any product between each product use
session. This artiﬁcial situation resulted from study design con-
straints needed for the nicotine PK measurements (Walele et al.,
2015). Any conclusions on subjective effects drawn from our
study should therefore be applied to real-life settings with care.
To conclude, the EVPs tested in this study, with different nico-
tine levels, with or without ﬂavours, had a similar short-term safety
proﬁle to an MHRA approved NRT product. Users of all EVPs,
regardless of their nicotine content, reported a decrease in nicotine
craving and withdrawal symptoms, which was, in the short-term,
similar to the decrease observed with a CC. The EVP studied here
may therefore offer a viable alternative to CCs for those ﬁnding it
difﬁcult to quit the behavioural and sensorial aspects of smoking.
These ﬁndings indicate that EVP use has the potential as an aid for
smoking reduction or cessation if it can meet the standards of ef-
ﬁcacy, safety and quality set by relevant regulatory authorities such
as the MHRA. Further work should however be carried out on the
use of the EVP in real-life settings.
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